Physician profile
Daniel R Co
NPI 1609858547
$1,666.95
in general payments reported to CMS, 2019-2025
23 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $95.19 · 2021: $144 · 2022: $185 · 2023: $283 · 2024: $593 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $233.38 | 2024-2025 | |
| Lilly USA, LLC | $223.60 | 2019-2024 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $212.55 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals Lp | $143.45 | 2024 | Farxiga |
| Abbvie INC. | $110.06 | 2023-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $100.92 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $94.52 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.52 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $62.38 | 2021-2024 | |
| Amarin Pharma, INC. | $60.56 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $59.80 | 2019-2022 | |
| Corcept Therapeutics | $40.08 | 2025 | Korlym |
| Abbott Laboratories | $39.19 | 2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $29.04 | 2021 | |
| Merck Sharp & Dohme LLC | $27.64 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24.05 | 2024 | Trelegy Ellipta |
| Lundbeck LLC | $23.66 | 2024 | Rexulti |
| Sanofi Pasteur INC. | $23.40 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.14 | 2023 | |
| Inspire Medical Systems, INC. | $18.88 | 2024 | Inspire |
| Pfizer INC. | $18.13 | 2020 | |
| Ibsa Pharma INC. | $17.75 | 2021 | |
| Mylan Specialty L.P. | $13.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Co listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.